2021. január 7., csütörtök 13:07 |
COVID-19: Use rapid tests to identify important biomarkers and predict the course of the disease. |
|
Moers, Germany, 7 January, 2021 (APA/OTS) - Whether it's a lung embolism or a heart attack - an infection with coronavirus can have life-threatening consequences. But how badly will different patients be affected by COVID-19? This can be determined by certain biomarkers. nal von minden GmbH's biomarker rapid tests from Germany deliver reliable results in just 15 minutes. |
An infection with coronavirus can run different courses. Some of
those affected display no symptoms, whereas in other patients the
course of the disease can be so severe that for some it is even
fatal. Biomarkers serve as a quantifiable indicator for the presence
and severity of an infection. They can be identified and evaluated
using a blood sample.
Studies have shown that the following biomarkers in particular play
an important role in the prognosis of an infection with COVID-19:
D-Dimer and troponin as well as C-reactive protein and the
inflammatory marker procalcitonin. Raised D-Dimer levels are
associated with deep vein thrombosis or a lung embolism, whereas
elevated troponin levels indicate heart damage. Raised inflammatory
markers have been identified in patients who have died.
nal von minden GmbH has developed rapid tests for the most
important biomarkers which can be carried out onsite. Reliable
results are available after just 15 minutes. "The faster important
biomarkers are determined, the sooner the correct - and potentially
life-saving - treatment measures can be implemented", says Roland
Meißner, CEO of nal von minden GmbH. If blood samples need to be
sent to an external laboratory for testing, hours or even days can
be lost.
The biomarker rapid tests are suitable for both hospital emergency
rooms and GP practices, where they serve to quickly clarify the
health status of a patient infected with coronavirus. Results can
immediately be discussed with the patient.
Roland Meißner: "We don't view our tests as being in competition
with laboratories, but rather as a valuable addition since
laboratories are already overburdened. In the interests of patients,
a decision regarding treatment must be made quickly."
Press contact: Gabriele Hellwig, +49 40 38 66 24 80,
info@hellwig-pr.de
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|